mposun

Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. server paling gacor 2023 Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20+ NHL cells in clinical trials. sobat168 Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy In this study, we summarized several latest